Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 53% Improvement Relative Risk c19early.org/s Siraj et al. Remdesivir for COVID-19 LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 1,000 patients in India (March - December 2020) Lower mortality with remdesivir (p<0.000001) Siraj et al., Indian J. Clinical Practice, 32:9 Favors remdesivir Favors control
Efficacy of Various Treatment Modalities on Patient-related Outcome in Hospitalized COVID-19 Patients – A Retrospective Study
Siraj et al., Indian Journal of Clinical Practice, 32:9
Siraj et al., Efficacy of Various Treatment Modalities on Patient-related Outcome in Hospitalized COVID-19 Patients – A.., Indian Journal of Clinical Practice, 32:9
Feb 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,000 COVID+ hospitalized patients in India, showing lower mortality with famotidine and remdesivir in multivariable logistic regression.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
risk of death, 52.9% lower, RR 0.47, p < 0.001, treatment 108 of 413 (26.2%), control 197 of 587 (33.6%), adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Siraj et al., 28 Feb 2022, retrospective, India, peer-reviewed, median age 56.0, 13 authors, study period March 2020 - December 2020.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: ORIGINAL RESEARCH Efficacy of Various Treatment Modalities on Patient-related Outcome in Hospitalized COVID-19 Patients – A Retrospective Study FARHANA SIRAJ*, NAZIA MEHFOOZ†, SUHAIL MANTOO*, AFSHAN SHABIR‡, TAJAMUL HUSSAIN#, SYED MUDASIR QADRI¥, UMAR HAFIZ£, AJAZ NABI KOUL§, MUSHTAQ DANGROO¶, MUZAFFAR BINDROO^, FAYAZ SOFI⇑, SONAULLAH SHAHψ, RAFI JANφ Abstract Background: The outbreak of coronavirus disease 2019 (COVID-19) caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) began in China, in December 2019, and was declared a pandemic by WHO on March 11, 2020. The treatment is evolving and is mostly supportive in nature. Material and methods: This was a single-center retrospective study that included confirmed COVID-19 cases treated at our institute (a tertiary care hospital in Jammu and Kashmir, India), between March 2020 and December 2020. Patients with age more than 18 years were included in the study. Results: On evaluating the effect of various drug therapies used in management of COVID-19 patients of all severity, use of remdesivir and famotidine was associated with significantly higher odds of survival. In subgroup of patients with severe disease, use of systemic steroids was associated with significantly higher odds of survival in addition to remdesivir and famotidine. In patients with severe COVID-19 illness, likelihood of survival was significantly higher in those who received combination of systemic steroids plus remdesivir compared to steroids and remdesivir alone. Conclusion: Steroids were effective in severe COVID-19 illness and the combination of steroids and remdesivir was more effective in severe illness. There is a need to undertake more large scale prospective randomized trials to determine the most effective drug therapies to treat the sick patients and prevent worsening of mild cases. Keywords: Pandemic, COVID-19 illness, SARS-CoV-2, severe COVID-19 T he outbreak of coronavirus disease 2019 (COVID-19) caused by novel severe acute respiratory syndrome coronavirus 2 (SARS‑ CoV-2) began in Wuhan, China, in December 2019 and was designated as a pandemic by the World *Assistant Professor, Dept. of Internal Medicine †Assistant Professor, Dept. of Pulmonary Medicine ‡Assistant Professor, Dept. of Geriatrics #Senior Resident, Dept. of Pulmonary Medicine ¥Associate Professor, Dept. of Internal Medicine £Associate Professor, Dept. of Geriatrics §Additional Professor, Dept. of Internal Medicine ^Assistant Professor ¶Additional Professor ⇑Professor Dept. of Rheumatology ψProfessor φProfessor and Head Dept. of Pulmonary Medicine, SK Institute of Medical Sciences, Soura, Srinagar, J&K Address for correspondence Dr Farhana Siraj Assistant Professor, Dept. of Internal Medicine, SK Institute of Medical Sciences, Srinagar -190 011, J&K E-mail: bagdadifarhana6@gmail.com Health Organization (WHO) on March 11, 2020.1,2 The spectrum of COVID-19 ranges from asymptomatic infection to mild respiratory tract illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure and death.3 A number of clinical trials have evaluated different treatment modalities in the management of COVID-19 illness and many more are under way, primarily assessing the clinical outcome in terms of accelerating the viral clearance, reduction in duration of symptoms, progression of disease, need for mechanical ventilation and mortality.4,5 Only few of these treatment interventions have shown significant..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit